Stentys said it’s closed the deal on the €1 million ($1.4 million) deal to acquire the Peel Away stent delivery system.
The cash-and-stock deal is the 1st strategic acquisition for Stentys, which makes a line of bare-metal and drug-eluting coronary stents.
Princeton, N.J.- and Paris-based Stentys has said it plans to integrate the technology into the delivery system for its stents portfolio, aiming to have the new system on the market in 2015.
The Cappella technology is cleared for the European market and is used as part of Cappella’s Sideguard coronary bifurcation stent, according to a press release. Cappella will keep the rights to the technology for use with the Sideguard stent "and for other potential applications including peripheral vascular indications," according to the release.
"This is Stentys’ 1st strategic acquisition, and it results from our active research efforts, including constant monitoring of the landscape for complementary tools to add to our portfolio. We are very excited about the potential for the Cappella Peel Away catheters to offer cardiologists an even friendlier user experience for implantation of our stents and allow more heart attack patients to benefit from Stentys’ self-apposing technology," co-founder & CEO Gonzague Issenmann said in when the deal was announced earlier this month.